Dermatology and Therapy最新文献

{"title":"Long-Term Disease Control During Continuous Treatment with Upadacitinib and Baricitinib for Moderate-to-Severe Atopic Dermatitis: a Real-World Monocentric Retrospective Study.","authors":"Francesco D'Oria, Costanza Falcidia, Giulio Foggi, Matteo Bianco, Ruggero Cascio Ingurgio, Angela Alfano, Luciano Ibba, Mario Valenti, Antonio Costanzo, Alessandra Narcisi, Luigi Gargiulo","doi":"10.1007/s13555-026-01940-6","DOIUrl":"https://doi.org/10.1007/s13555-026-01940-6","url":null,"abstract":"<p><strong>Introduction: </strong>Real-world evidence on long-term effectiveness and safety of oral Janus kinase (JAK) inhibitors in atopic dermatitis (AD) remains limited. This study evaluated sustained long-term clinical and patient-reported disease control and safety during continuous treatment with upadacitinib 30 mg or baricitinib 4 mg.</p><p><strong>Methods: </strong>This monocentric retrospective study included adults with moderate-to-severe AD treated at IRCCS Humanitas Research Hospital. Eligible patients had baseline assessments and completed longitudinal follow-ups while remaining on their assigned JAK inhibitor. Outcomes were assessed through week 260 for upadacitinib and week 312 for baricitinib and included Eczema Area and Severity Index (EASI) 75/90/100, EASI ≤ 7/≤ 3, Investigator Global Assessment (IGA) 0/1, mean EASI, Peak Pruritus Numerical Rating Scale (PP-NRS), Sleep Disturbance Numerical Rating Scale (SD-NRS) improvement and remission endpoints, and safety. Between-treatment comparisons were considered exploratory only.</p><p><strong>Results: </strong>The long-term cohort included 41 patients: 34 received upadacitinib and 7 baricitinib. At week 260, EASI 75, EASI 90, EASI ≤ 7, and EASI ≤ 3 were achieved by 97.1%, 91.2%, 100.0%, and 91.2% of upadacitinib-treated patients, respectively. In the baricitinib group, EASI 75 was maintained by all patients from week 32 to week 312, and EASI 90, EASI ≤ 7, and EASI ≤ 3 were achieved by all patients at week 312. IGA 0/1 and mean EASI indicated sustained low disease activity during follow-up. At week 260, ΔPP-NRS ≥ 4 and ΔSD-NRS ≥ 4 were maintained in 82.4% and 73.5% of upadacitinib-treated patients and in 85.7% and 71.4% of baricitinib-treated patients, with corresponding baricitinib rates maintained at week 312. Adverse events were infrequent, with no serious adverse events, treatment interruptions, or permanent discontinuations in the long-term cohort.</p><p><strong>Conclusions: </strong>In selected patients remaining on continuous treatment, upadacitinib and baricitinib were associated with sustained long-term clinical and patient-reported control of moderate-to-severe AD. Larger prospective studies are needed to clarify outcomes after dose reduction or discontinuation and the potential for deeper disease remodeling.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149105445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"International Validation of the Short Version of the Quality of Life Relevance-Acne Questionnaire.","authors":"Pavel V Chernyshov, Nives Pustišek, Dimitra Koumaki, Tetiana Pochynok, Hilayda Karakok Kisla, Liana Manolache, Carmen Salavastru, Alina Suru, Adelina Sendrea, Razvigor Darlenski, Michael J Boffa, Petra Magri Gatt, Jean-Paul Claudel, Nicole Auffret, Brigitte Dréno","doi":"10.1007/s13555-026-01941-5","DOIUrl":"https://doi.org/10.1007/s13555-026-01941-5","url":null,"abstract":"<p><strong>Introduction: </strong>The objective of the present study was to conduct an international validation of the Quality of Life Relevance-Acne Short Version (QOLRELEVANCE-ACNE-SV) and to propose a severity grading system for its scores.</p><p><strong>Methods: </strong>All patients were asked to fill in the QOLRELEVANCE-ACNE-SV and Dermatology Life Quality Index (DLQI). Global acne severity was assessed separately by dermatologists and patients. Students without acne were asked to fill in the QOLRELEVANCE-ACNE-SV questionnaire on a voluntary basis.</p><p><strong>Results: </strong>The results of 530 patients with acne across five countries that collected more than 100 results each (Croatia, Greece, Ukraine, Turkey and Romania) were analysed. The results from France, Bulgaria and Malta that collected fewer results were used for assessment of internal consistency. The results from Bulgaria were also used to check test-retest reliability. Cronbach's alpha was 0.84-0.95 in all countries except Bulgaria and Malta (0.74 and 0.75, respectively). Correlations between QOLRELEVANCE-ACNE-SV scores and DLQI scores were 0.54-0.85 except for Turkey (0.33); mean global acne severity assessed by a dermatologist 0.44-0.90 and self-assessment of the global acne severity 0.45-0.88 except for Romania (0.28 and 0.38, respectively). Among volunteers without acne, all QOLRELEVANCE-ACNE-SV questionnaire scores were 0. Test-retest reliability of the QOLRELEVANCE-ACNE-SV was good (r = 0.90, p < 0.001). The following grading system of the QOLRELEVANCE-ACNE-SV scores was accepted: total scores < 6 correspond to a mild effect, scores from 6 to 8 correspond to moderate effect and scores > 8 correspond to severe effect on a patient's life.</p><p><strong>Conclusions: </strong>Our study confirmed high specificity of the QOLRELEVANCE-ACNE-SV questionnaire for patients with acne, good test-retest reliability, good or excellent internal consistency in all countries except Bulgaria and Malta, where it rated as acceptable, good or moderate convergent validity with DLQI (except Turkey) and with global acne severity (except Romania). A grading system of the QOLRELEVANCE-ACNE-SV questionnaire scores was accepted.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149105462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dermatologists' Perspectives and Real-World Assessment of Alopecia Areata Severity, Burden, and Healthcare Resource Utilization in Adults in the Kingdom of Saudi Arabia.","authors":"Mohammed Abdulaziz F Al Ajlan, Khalidah A Alenzi, Mohammed A Al-Haddab, Ibtisam AlHarbi, Abdulrahman Alturaiki, Mohammad Saeed Arsalan, Ayman Behiry, Samantha K Kurosky, Gerardo A Encinas, Peter Anderson, Ashley S Cha-Silva, Shailja Vaghela, Juliana Machado Canosa","doi":"10.1007/s13555-026-01873-0","DOIUrl":"10.1007/s13555-026-01873-0","url":null,"abstract":"<p><strong>Introduction: </strong>Alopecia areata (AA), an autoimmune disease, causes hair loss on the scalp, face, and body, with a prevalence of approximately 2% in the Middle East. AA is associated with significant impacts to patient quality of life (QoL). This study described dermatologist perceptions and experiences treating AA in the Kingdom of Saudi Arabia (KSA) while new treatments were introduced, and examined patient disease burden and unmet treatment need.</p><p><strong>Methods: </strong>Data were analyzed from the Adelphi Real World AA Disease Specific Programme™, conducted September 2022-March 2023. Dermatologists rated their agreement with statements on diagnosing/managing AA and provided clinical and treatment information for four patients (mild/moderate AA: one each; severe/very severe AA: two). A subset of these patients completed the SKINDEX-16, Hospital Anxiety and Depression Scale (HADS), and the Work Productivity and Activity Impairment-AA (WPAI-AA) questionnaires. Analyses were stratified by percent scalp hair loss (SHL).</p><p><strong>Results: </strong>A total of 50 dermatologists and 185 patients were included. Most dermatologists reported severe AA was difficult to treat owing to lack of effective therapies. A median of 51.5% SHL was reported as typical of severe AA. Impact of AA on patient QoL was the most frequently reported factor informing disease severity. Overall, 52.4% of patients had severe or very severe AA (as assessed by their physician). Approximately one-third of patients had abnormal anxiety and depression scores as measured by HADS. Patients with ≤ 20% SHL generally had lower mean Skindex-16 scores (impact of AA on QoL). Patients with ≥ 50% SHL reported greater work and activity impacts on the WPAI-AA. Most patients were receiving their first AA treatment, with the most common treatments differing by SHL category. Healthcare resource utilization and costs were greater among patients with ≥ 50% SHL.</p><p><strong>Conclusions: </strong>In the KSA, the burden of AA extends beyond SHL to include both mental health and economic burdens, highlighting the need for effective treatments.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"4947-4960"},"PeriodicalIF":4.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13650089/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148757444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gut-Brain-Skin Axis: From Mechanistic Insights to Translational Applications in Neurocosmetics.","authors":"Ruohan Zhao, Huilin Xu, Yirui Zhu, Huailong Chang, Bin Liu, Zhongwang Liu","doi":"10.1007/s13555-026-01892-x","DOIUrl":"10.1007/s13555-026-01892-x","url":null,"abstract":"<p><p>The gut-brain-skin axis is a proposed integrative framework describing interactions among the gastrointestinal tract, skin, and nervous system through neural, endocrine, immune, and microbial processes. Accumulating evidence has redefined the skin as a sophisticated neuro-immune-endocrine organ rather than a passive barrier, providing the fundamental mechanistic basis for the burgeoning interdisciplinary field of neurocosmetics. However, most existing reviews have focused on the unidirectional regulation from gut to skin and from brain to skin, lacking systematic analysis of the reverse signaling from skin to nervous system and its potential for cosmetic transformation. This article addresses this gap by providing a comprehensive, mechanism-oriented integrative discussion of the gut-brain-skin axis, with a focus on the ascending skin-to-central signal pathways and their significance for neurocosmetics. This review first establishes the gut-brain axis as the core framework for barrier organ-central nervous system crosstalk, then systematically delineates the key molecular and cellular mechanisms underlying the skin-brain axis-the central pillar of neurocosmetics. This article further identifies conserved regulatory hubs and shared pathological mechanisms that underlie the comorbidity of atopic dermatitis, depression, and irritable bowel syndrome. Building on this integrated framework, this review evaluates several mechanistically grounded neurocosmetic development strategies, identifies pressing translational challenges, and proposes priority directions for future research. In summary, this article provides an evidence-based framework for understanding how the gut-brain-skin axis underpins the scientific basis of neurocosmetics and proposes a translational skincare framework that integrates overall homeostasis, stress protection, and emotional health.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"4823-4855"},"PeriodicalIF":4.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13650220/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148789416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Elongated Corkscrew Hairs as a Possible Novel Trichoscopic Sign in Endothrix Tinea Capitis Affecting Adults with Immunosuppression.","authors":"Asmahane Souissi, Raquel de Melo Carvalho, Malek Ben Slimane, Mohammad Jafferany, Daniel Fernandes Melo","doi":"10.1007/s13555-026-01902-y","DOIUrl":"10.1007/s13555-026-01902-y","url":null,"abstract":"<p><strong>Introduction: </strong>Tinea capitis is a fungal infection of the scalp in which trichoscopy plays an important role by allowing early identification of characteristic hair shaft alterations before mycological confirmation.</p><p><strong>Methods: </strong>We describe two adult women who are immunosuppressed with endothrix tinea capitis caused by Trichophyton violaceum.</p><p><strong>Results: </strong>Both patients presented with diffuse scalp alopecia and scaling. Trichoscopic examination revealed unusually elongated corkscrew hairs, and fungal cultures confirmed the diagnosis.</p><p><strong>Conclusions: </strong>Elongated corkscrew hairs represent a previously unreported trichoscopic pattern in chronic endothrix tinea capitis. Awareness of this finding may facilitate earlier diagnostic suspicion and prompt targeted mycological investigation in patients who are immunosuppressed.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"5257-5262"},"PeriodicalIF":4.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13650081/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148850099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Expanding Role of GLP-1 Receptor Agonists and Dual GIP/GLP-1 Agonists in Dermatology: From Immunometabolism to Clinical Practice.","authors":"Caterina M Giorgio, Carola Romanò, Mariachiara Arisi, Mariateresa Rossi, Marina Venturini, Sara Mezzana, Laura Grigolato, Benedetta Galli, Maria M Nicoletti, Cesare Tomasi, Gaetano Licata","doi":"10.1007/s13555-026-01916-6","DOIUrl":"10.1007/s13555-026-01916-6","url":null,"abstract":"<p><p>Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonists (dual GIP/GLP-1 agonists) have rapidly changed the management of obesity and type 2 diabetes mellitus. Beyond their effects on weight reduction and glycemic control, these agents exert pleiotropic effects on inflammation, adipose tissue biology, endothelial function and tissue repair, properties of growing relevance to dermatology, where several chronic inflammatory diseases are closely linked to obesity, insulin resistance and systemic low-grade inflammation. Current evidence suggests potential clinical benefit in psoriasis and hidradenitis suppurativa, encouraging signals regarding wound healing and a generally favorable cutaneous safety profile, although cutaneous adverse events, including injection site reactions, hypersensitivity, alopecia and rare autoimmune eruptions, have been increasingly reported. This review summarizes the immunometabolic rationale, current clinical evidence, the dermatologic safety profile and future perspectives of GLP-1RAs and dual GIP/GLP-1 agonists in dermatology. Although available data remain heterogeneous and largely observational outside psoriasis and hidradenitis suppurativa, these therapies may represent a new class of systemic immunometabolic modulators with practical implications for inflammatory, surgical and aesthetic dermatology.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"4897-4912"},"PeriodicalIF":4.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13650102/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148954901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of the First Adalimumab Biosimilar in Chinese Children with Severe Plaque Psoriasis: The PISCES Study, a Multicenter Prospective Study.","authors":"Yirong Huang, Ting Pan, Xin Shi, Guoqiang Zhang, Fang Cheng, Songmei Geng, Heng Gu, Shanshan Li, Qingchun Diao, Xiaohua Wang, Yonghong Lu, Chao Ji, Yuzhen Li, Yuling Shi, Jun Gu, Lingling Chen","doi":"10.1007/s13555-026-01897-6","DOIUrl":"10.1007/s13555-026-01897-6","url":null,"abstract":"<p><strong>Introduction: </strong>Adalimumab, a monoclonal antibody targeting tumor necrosis factor-alpha, has been approved for the treatment of severe plaque psoriasis in children aged 4 years and older. Data on its use in the clinical management of pediatric psoriasis in China remains limited. This study is the first prospective analysis of the adalimumab biosimilar (GELELI®, the first biosimilar of adalimumab approved in China, and QLETLI® in the UK) safety and effectiveness for severe pediatric plaque psoriasis in China.</p><p><strong>Methods: </strong>Weight-based dosage was administered to 80 patients (ages 4-18 years) from multiple centers. Primary endpoints included the proportions of patients achieving PASI75 and PGA 0/1 at week 16.</p><p><strong>Results: </strong>The mean psoriasis area and severity index (PASI) score decreased from 15.31 ± 8.375 at baseline to 6.29 ± 4.208 at week 4. PASI 50/90/100 response rates were 91.1%, 49.4%, and 21.5% at week 12. At week 16, 81.0% and 68.4% of patients attained PASI75 and PGA 0/1, respectively. The incidence of adverse events was 82.5%. Adverse drug reactions accounted for 62.5%. No serious adverse events were reported.</p><p><strong>Conclusions: </strong>The biosimilar demonstrates efficacy and safety in the treatment of Chinese children with severe plaque psoriasis, consistent with clinical trial data for the originator drug.</p><p><strong>Trial registration: </strong>Clinicaltrials.gov: NCT05803187.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"5161-5173"},"PeriodicalIF":4.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13650105/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148900251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"AI-Assisted Quantitative Reflectance Confocal Microscopy Reveals Modulation of Senescence-Associated Epidermal Morphometric Features by a Topical TGF-β Mimetic, XEP™-716 Miniprotein™.","authors":"Hanane Chajra, Nicolas Rayroux, Corinne Granger, Lionel Breton, Pedro Contreiras PInto, Thibaut Saguet, Jean-Marc Le Doussal","doi":"10.1007/s13555-026-01945-1","DOIUrl":"https://doi.org/10.1007/s13555-026-01945-1","url":null,"abstract":"<p><strong>Introduction: </strong>Epidermal aging is characterized by progressive structural alterations, including reduced keratinocyte density, altered cellular morphology, and widened intercellular spacing (ICS). Reflectance confocal microscopy (RCM) combined with artificial intelligence (AI)-assisted image analysis enables non-invasive quantification of these changes in vivo. This secondary analysis of RCM images reported in a previously published randomized split-face clinical trial aimed to identify quantitative morphometric features associated with chronological aging and to evaluate their modulation following topical application of the transforming growth factor-beta (TGF-β) mimetic XEP™-716 Miniprotein™ (Activen SA, Lausanne. Switzerland).</p><p><strong>Methods: </strong>Previously acquired baseline RCM images from 49 women (age 40-60 years) were analyzed for associations with chronological age. Treatment effects were assessed in 25 women from the 2.5% arm of a 56-day randomized, double-blind, split-face study comparing XEP™-716 Miniprotein™ 2.5% with vehicle. AI-assisted image analysis quantified keratinocyte density, cellular circularity, and ICS in the stratum granulosum (SG) and the stratum spinosum (SS). Cells with circularity ≤ 0.439 were classified as low-circularity cells and those ≥ 0.440 circularity as morphologically normal. Treatment effects were assessed using linear mixed-effects models.</p><p><strong>Results: </strong>Stratum granulosum total and normal keratinocyte densities were nominally significantly associated with age (p = 0.015 and p = 0.023, respectively). Compared with vehicle, XEP™-716 Miniprotein™ used at 2.5% was associated with nominally significant increases in normal keratinocyte density (p = 0.028) and the circularity of low-circularity cells (p = 0.018), and with decreases in ICS thickness (p = 0.030) and low-circularity cell density (p = 0.044) in the SG. In the SS, there was a non-significant trend towards reduced low-circularity cell density (p = 0.075).</p><p><strong>Conclusion: </strong>Artificial intelligence-assisted quantitative RCM can identify age-associated epidermal morphometric features, predominantly in the SG, and detect their modulation following topical treatment. XEP™-716 Miniprotein™ at 2.5% showed consistent treatment-associated changes across several morphometric parameters with nominal statistical significance. These exploratory findings warrant prospective validation against molecular senescence markers and functional barrier measurements.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149105414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Effectiveness and Safety of Bimekizumab for Moderate-to-Severe Hidradenitis Suppurativa: A Multicenter Retrospective Study from the Italian Landscape HS (IL-HS).","authors":"Mario Valenti, Ruggero Cascio Ingurgio, Luciano Ibba, Edoardo Cammarata, Raffaele D Caposiena Caro, Andrea Carugno, Martina Dragotto, Claudio Marasca, Piergiorgio Malagoli, Fabrizio Martora, Angelo V Marzano, Matteo Megna, Santo R Mercuri, Francesco Messina, Alessandra Michelucci, Chiara Moltrasio, Giovanni Paolino, Federica Repetto, Simone Ribero, Luigi Rossiello, Emanuele Trovato, Nicola Zerbinati, Antonio Costanzo, Alessandra Narcisi, Valentina Dini","doi":"10.1007/s13555-026-01891-y","DOIUrl":"10.1007/s13555-026-01891-y","url":null,"abstract":"<p><strong>Introduction: </strong>Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease characterized by painful nodules, abscesses, draining tunnels and substantial impairment in quality of life. Bimekizumab, a monoclonal antibody that selectively inhibits interleukin-17A and interleukin-17F, was recently approved in Italy for the treatment of moderate-to-severe HS. However, real-world evidence remains limited.</p><p><strong>Methods: </strong>This was a retrospective multicenter study of patients with HS treated with bimekizumab across Italian dermatology referral centers. Effectiveness was assessed at weeks 4, 16 and 24 using the following measurement tools and scales: Hidradenitis Suppurativa Clinical Response (HiSCR), HiSCR75, HiSCR90, HiSCR100 (at least 75%, 90% and 100% reductions in AN count, respectively, plus HiSCR criteria), the International Hidradenitis Suppurativa Severity Score System 55% reduction (IHS4-55), International Hidradenitis Suppurativa Severity Score System (IHS4), draining tunnel count, abscess and inflammatory nodule (AN) count, AN50 (at least 50% reduction in AN), pain numerical rating scale (NRS-pain), NRS50 (as at least a 50% reduction in NRS-pain compared with baseline) and Dermatology Life Quality Index (DLQI). Safety outcomes included adverse events, rescue therapies and concomitant treatments.</p><p><strong>Results: </strong>A total of 100 patients were included in the study among whom 56% were male and the mean age was 37.3 years. Median body mass index was 26.8 kg/m², 75% had Hurley stage III disease and 80% had prior biologic exposure. HiSCR was achieved by 36 of 100 (36.0%) patients at week 4, 60 of 100 (60.0%) patients at week 16 and 41 of 53 (77.4%) patients at week 24. HiSCR75 was achieved by 24 of 100 (24.0%) patients, 48 of 100 (48.0%) patients and 35 of 53 (66.0%) patients at weeks 4, 16 and 24, respectively. Median IHS4 decreased from 18 at baseline to 7 at week 24; median draining tunnel count decreased significantly from baseline at all visits, median AN count decreased from 3.5 to 1, median NRS-pain decreased from 8 to 3, and median DLQI decreased from 19.5 to 7. IHS4-55 was achieved by 54.7% of evaluable patients at week 24. Flare rates remained below 10% throughout follow-up. Any adverse event was reported in 22 patients (22.0%).</p><p><strong>Conclusion: </strong>In this multicenter Italian real-world cohort, bimekizumab was associated with early clinical improvement and meaningful reductions in disease activity, pain and quality-of-life burden; week-24 estimates should be interpreted in light of administrative censoring.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"5069-5084"},"PeriodicalIF":4.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13650090/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148849843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety of Icotrokinra Through 1 Year for the Treatment of Moderate-to-Severe Plaque Psoriasis and Psoriasis Affecting High-Impact Sites: Pooled Results Across the ICONIC-LEAD, ICONIC-TOTAL, and ICONIC-ADVANCE 1 and 2 Phase 3 Trials.","authors":"Mark G Lebwohl, Melinda Gooderham, Richard B Warren, Lawrence F Eichenfield, Jessica H Rubens, Tracy Cardillo, Christopher Russo, Cynthia M C DeKlotz, Megan Miller-Kassamali, Luis Anaya Velarde, Ming-Chun Hsu, Shu Li, Ya-Wen Yang, Sarah Ofori, Robert Bissonnette, Jennifer Soung, Adelaide A Hebert, Linda Stein Gold","doi":"10.1007/s13555-026-01885-w","DOIUrl":"10.1007/s13555-026-01885-w","url":null,"abstract":"<p><strong>Introduction: </strong>Icotrokinra, a first-in-class targeted oral peptide, precisely blocks the interleukin (IL)-23 receptor and inhibits IL-23 pathway signaling. In phase 3 studies (ICONIC-LEAD, ICONIC-TOTAL, ICONIC-ADVANCE 1 and 2), icotrokinra provided superior skin clearance versus placebo and deucravacitinib in adults and adolescents with moderate-to-severe psoriasis and psoriasis affecting high-impact sites. This analysis evaluates icotrokinra safety through 1 year using pooled data from these four studies.</p><p><strong>Methods: </strong>Icotrokinra-randomized participants received 200-mg pills once daily, and placebo-randomized participants crossed over to icotrokinra at week 16; participants randomized to deucravacitinib 6 mg (ICONIC-ADVANCE 1 and 2 only) switched to icotrokinra at week 24. Pooled safety data are summarized for the placebo-controlled period (week 0-16, all studies), active-controlled period (week 0-24, ICONIC-ADVANCE 1 and 2), and through week 52 (all studies).</p><p><strong>Results: </strong>During the placebo-controlled period across all studies, 568 participants received placebo and 1296 received icotrokinra. From week 0 to 24 in the ICONIC-ADVANCE studies, 632 participants received icotrokinra and 634 received deucravacitinib. Through week 52, 2400 icotrokinra-treated participants contributed 1840 participant-years [PY] of follow-up. Through week 16, in the icotrokinra and placebo groups, respectively, exposure-adjusted incidence rates/100 PY of adverse events (AEs; 232 and 269), serious AEs (5.2 and 6.6), infections (91 and 104), and AEs leading to discontinuation (6.6 and 10.0) were comparable between groups. Through week 24, in the ICONIC-ADVANCE studies, rates/100 PY with icotrokinra versus deucravacitinib were as follows: AEs, 204 vs 265; serious AEs, 6.4 vs 7.2; infections, 81 vs 119; AEs leading to discontinuation, 5.7 vs 6.8. Through week 52, event rates/100 PY in icotrokinra-treated participants were as follows: AEs, 167; serious AEs, 4.6; infections, 76; AEs leading to discontinuation, 3.0.</p><p><strong>Conclusion: </strong>In this analysis of 2400 icotrokinra-treated participants with psoriasis followed through 1 year, icotrokinra demonstrated favorable safety; event rates through week 16 were similar to placebo and remained consistent through week 52.</p><p><strong>Clinicaltrials: </strong>GOV: NCT06095115, NCT06095102, NCT06143878, NCT06220604. Infographic available for this article. INFOGRAPHIC.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"5049-5068"},"PeriodicalIF":4.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13650227/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148849814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}